Bristol Myers Squibb reported that its investigational drug iberdomide in combination with Darzalex and dexamethasone met a key primary endpoint in a Phase 3 trial for relapsed or refractory multiple myeloma. The combination improved the rate of minimal residual disease negativity compared to a standard regimen, reflecting a deeper eradication of malignant cells. While progression-free survival data remain forthcoming, results so far position iberdomide as a promising successor to existing blood cancer therapies. Bristol Myers plans regulatory submissions based on these findings to support approval.